Compare BSAC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | NBIX |
|---|---|---|
| Founded | 1977 | 1992 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 13.9B |
| IPO Year | 1994 | 1996 |
| Metric | BSAC | NBIX |
|---|---|---|
| Price | $36.98 | $137.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 20 |
| Target Price | $29.50 | ★ $175.85 |
| AVG Volume (30 Days) | 367.7K | ★ 1.0M |
| Earning Date | 01-30-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | 22.83 | ★ 41.95 |
| EPS | 0.01 | ★ 4.67 |
| Revenue | $2,560,142,282.00 | ★ $2,860,500,000.00 |
| Revenue This Year | $35.78 | $21.24 |
| Revenue Next Year | $6.84 | $8.59 |
| P/E Ratio | ★ $14.87 | $29.43 |
| Revenue Growth | 10.15 | ★ 21.45 |
| 52 Week Low | $20.77 | $84.23 |
| 52 Week High | $37.72 | $160.18 |
| Indicator | BSAC | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 49.67 |
| Support Level | $36.37 | $136.46 |
| Resistance Level | $37.60 | $142.82 |
| Average True Range (ATR) | 0.95 | 3.78 |
| MACD | -0.06 | 0.65 |
| Stochastic Oscillator | 69.55 | 53.72 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.